-
Product Insights
NewLikelihood of Approval Analysis for Community Acquired Pneumonia
Overview How likely is it that the drugs in Community Acquired Pneumonia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Community Acquired Pneumonia Overview Community-acquired pneumonia (CAP) is defined as pneumonia...
-
Product Insights
NewNet Present Value Model: Nippon Shinyaku Co Ltd’s CAP-1002
Empower your strategies with our Net Present Value Model: Nippon Shinyaku Co Ltd's CAP-1002 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Cap Des Biches Gas Fired Combined Cycle Power Plant
Cap Des Biches Gas Fired Combined Cycle Power Plant is a thermal project located in Dakar, Senegal. The project is owned by Senegal National Electricity Agency; West African Energy SA and is developed by West African Energy SA. The project is currently under construction. Empower your strategies with our Cap Des Biches Gas Fired Combined Cycle Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will...
-
Product Insights
A3 Capital / Gaw Cap – Cyberjaya Data Centre – Kuala Lumpur
The A3 Capital / Gaw Cap – Cyberjaya Data Centre – Kuala Lumpur project involves the construction of a 17,000m2, seven-story data center comprising 1,830 cabinets with a capacity of 12MW in Cyberjaya, Selangor, Malaysia. Equip yourself with the essential tools needed to make informed and profitable decisions with our A3 Capital / Gaw Cap – Cyberjaya Data Centre – Kuala Lumpur report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Anumigilimab in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anumigilimab in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anumigilimab in Rheumatoid Arthritis Drug Details: Anumigilimab (CSL324) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Silmitasertib in Basal Cell Carcinoma (Basal Cell Epithelioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Silmitasertib in Basal Cell Carcinoma (Basal Cell Epithelioma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Silmitasertib in Basal Cell Carcinoma (Basal Cell...
-
Company Insights
Innovation and Patenting activity of CAP SA Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CAP SA Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Reparixin in Community Acquired Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Reparixin in Community Acquired Pneumonia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Reparixin in Community Acquired Pneumonia Drug Details: Reparixin (Repertaxin) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Reparixin in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Reparixin in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Reparixin in Triple-Negative Breast Cancer (TNBC) Drug Details: Reparixin (Repertaxin)...